Skip to main content
. 2023 Jun 4;19(9):2934–2956. doi: 10.7150/ijbs.81961

Figure 4.

Figure 4

Colchicine or AG-1478 improves short-term survival and reduces the recurrence of AF in LPS-stimulated mice. A. Schematic of animal experiments. B-C. Bar graphs to compare the TNF-α and IL-6 levels determined by ELISA assay between baseline mice (control group), mice treated with LPS alone (LPS group), mice treated with LPS and colchicine (LPS + colchicine group), and mice treated with LPS and AG-1478 (LPS + AG-1478 group), respectively. n= 3-6 mice. D. Representative images of body-surface ECGs for the control group, LPS group, LPS + colchicine group, and LPS + AG-1478 group. E-H. Bar graphs to compare QR, QTc, QRS and PR between the control group, LPS group, LPS + colchicine group, and LPS + AG-1478 group. n= 10-12 mice. I. Bar graph to compare the number of AF episodes between the control group, LPS group, LPS + colchicine group, and LPS + AG-1478 group. n= 10-13 mice. J. Scatter dot plot to compare the AF episode durations between the control group, LPS group, LPS + colchicine group, and LPS + AG-1478 group. n= 10-13 mice. The numbers in bars in Figure 4I represent the number of mice, each mouse had two AF episode durations according to protocol and shown in Figure 4J. K. Representative images of intracardiac pacing ECG. Red circles denote the AF events. L-M. Survival curves of colchicine or AG-1478 treatment at different doses in LPS-stimulated mice.